ArticleAddiction science & clinical practice2025
Implementing incentives in family medicine for opioid use disorder treatment: a qualitative inquiry on provider and patient preferences for a low magnitude reward program compatible with buprenorphine treatment.
Article in Addiction science & clinical practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
10 authors.
Funding
Abstract
backgroundIncentive programs are an effective yet underutilized behavioral intervention that can improve outcomes in medication for opioid use disorder (MOUD) treatment. Contingency Management (CM) is a rigorous incentive program run per seven evidence-based principles (e.g. objectively verifiable target behaviors, frequent opportunities for incentives). Prior implementation attempts have focused on implementing CM in specialized addiction clinics with methadone as the primary medication treatment. However, many people get MOUD from less specialized, more accessible family medicine clinics. These clinics might also benefit from the use of incentive programs, yet present unique challenges for implementation. For example, family medicine clinics typically use buprenorphine as their primary medication, which requires less intensive dosing schedules than methadone and thus provides fewer incentive opportunities. As an initial step in user-centered design of a CM-informed incentive program for the family medicine context, we conducted qualitative interviews with patients and staff in the buprenorphine treatment program of a family medicine department. We gathered and analyzed qualitative data on CM knowledge, preferred program parameters, and implementation considerations.
methodParticipants (N = 24) were buprenorphine treatment staff (n = 12) and patients (n = 12). Participants completed 30-50-minute semi-structured interviews, analyzed using rapid matrix analysis.
resultsParticipants had little experience with formal incentive programs, but generally viewed incentives as acceptable, appropriate, and feasible. Interviewees coalesced around having staff who were not MOUD prescribers run the program, consistent rather than escalating payments, and physical rewards delivered in-person. Potential challenges included medical record integration, demands on staff time, and confirmation of patients' goal completion.
conclusionsPatient and staff feedback was well-aligned, especially regarding rewards as an opportunity for staff-patient connection and the need for simplicity. Comparing end-user suggestions with the literature, some consensus suggestions (e.g. non-escalating rewards) highlighted feasible places to compromise on ideal effectiveness to gain implementability. However, others (e.g. use of self-report to verify goals) conflicted directly with CM principles and indicate where more intensive education, support, and monitoring will be needed for implementation fidelity. These findings inform user-centered design and iteration of an incentive program for this accessible, non-specialized family medicine setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.